Patent intelligence · WO
WO 2025051711
TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE
TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE
Patent details — WO 2025051711
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Mar 13, 2025
- Expiration
- Mar 8, 2045
- Applicant
- ASCENDIS PHARMA BONE DISEASES AS [DK]
- CPC classes
- A61K 38/ 29 A I, A61K/3829, A61P 5/ 18 A I, A61P 13/ 00 A I
Quick answer
WO 2025051711 (TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE) is held by ASCENDIS PHARMA BONE DISEASES AS [DK]. Status: granted. Granted Mar 13, 2025. Expires Mar 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASCENDIS PHARMA BONE DISEASES AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 29 A I, A61K/3829, A61P 5/ 18 A I, A61P 13/ 00 A I, A61P/1300, A61P/518
More from ASCENDIS PHARMA BONE DISEASES AS [DK]
Related pharmaceutical patents in our USPTO index.
-
WO 2024094673
RÉGIME DE TRAITEMENT À BASE DE PTH COMPRENANT DEUX COMPOSÉS PTH
granted -
US 2023321198
Dosage Regimen for a Controlled-Release PTH Compound
granted -
CA 3230895
TRAITEMENTS AVEC DES COMPOSES PTH A ACTION PROLONGEE
granted -
CA 3192772
AMELIORATION DU BIEN-ETRE PHYSIQUE ET MENTAL DE PATIENTS ATTEINTS D'HYPOPARATHYROIDISME
granted -
CA 3161101
TRAITEMENT DE L'HYPOPARATHYROIDISME
granted -
US 2020276276
PTH Prodrugs
granted -
CA 3129357
FORMULATIONS PHARMACEUTIQUES LIQUIDES DE CONJUGUES PTH
granted
Frequently asked questions
What is US patent 2025051711?
WO 2025051711 (TRAITEMENT PAR PTH D'UNE MALADIE RÉNALE CHRONIQUE) is held by ASCENDIS PHARMA BONE DISEASES AS [DK]. Status: granted. Granted Mar 13, 2025. Expires Mar 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025051711?
ASCENDIS PHARMA BONE DISEASES AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does WO 2025051711 expire?
Our index shows an expiration date of Mar 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.